ArticleOncotarget2015
Methyl-β-cyclodextrin up-regulates collagen I expression in chronologically-aged skin via its anti-caveolin-1 activity.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Adipocytes as core drivers of skin aging and novel targets for regeneration.Biogerontology · 2026Review
- Lipid Oxidation at the Crossroads: Oxidative Stress and Neurodegeneration Explored inAntioxidants (Basel, Switzerland) · 2025Review
- Physiological and pathological roles of caveolins in the central nervous system.Trends in neurosciences · 2024Review
- Article
- Caveolin-1 suppresses hippocampal neuron apoptosis via the regulation of HIF1α in hypoxia in naked mole-rats.Cell biology international · 2022Article
- Protective role of Cav-1 in pneumolysin-induced endothelial barrier dysfunction.Frontiers in immunology · 2022Article
- Involvement of caveolin-1 in skin diseases.Frontiers in immunology · 2022Review
- Contribution of Autophagy-Lysosomal Pathway in the Exosomal Secretion of Alpha-Synuclein and Its Impact in the Progression of Parkinson's Disease.Frontiers in molecular neuroscience · 2022Review
- Age-related increase in caveolin-1 expression facilitates cell-to-cell transmission of α-synuclein in neurons.Molecular brain · 2021Article
- ECM deposition is driven by caveolin-1-dependent regulation of exosomal biogenesis and cargo sorting.The Journal of cell biology · 2020Article
- Cyclic Oligosaccharides as Active Drugs, an Updated Review.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Caveolin-1, a master regulator of cellular senescence.Cancer metastasis reviews · 2020Review
- The importance of caveolins and caveolae to dermatology: Lessons from the caves and beyond.Experimental dermatology · 2020Review
- Caveolin as a Universal Target in Dermatology.International journal of molecular sciences · 2019Review
- Caveolin-1 in skin aging - From innocent bystander to major contributor.Ageing research reviews · 2019Review
- SMPDL3b modulates insulin receptor signaling in diabetic kidney disease.Nature communications · 2019Article
- Caveolin-1 as a pathophysiological factor and target in psoriasis.NPJ aging and mechanisms of disease · 2019Review
- Caveolin-1 as a target in prevention and treatment of hypertrophic scarring.NPJ Regenerative medicine · 2019Review
- Modulation of caveolae by insulin/IGF-1 signaling regulates aging ofEMBO reports · 2018Article
- Versatile Functions of Caveolin-1 in Aging-related Diseases.Chonnam medical journal · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Caveolin-1 (Cav-1) is one of the key molecules to modulate collagen metabolism in the skin. This study aimed to unravel the relationship between Cav-1 and collagen levels in the aged skin, and also to evaluate a new role of anti-Cav-1 agent as a collagen-modulating agent. A negative correlation between Cav-1 and collagen I (COL I) was detected in chronologically aged skin of humans and mice, which was further confirmed by Cav-1 knock-down or knock-out experiments. Next, we tested whether methyl-β-cyclodextrin (MβCD) as a chemical Cav-1 inhibitor could be developed as a collagen-modulating agent in the skin. Testing different conditions of MβCD injection via the intra-dermal route revealed that 2.5% MβCD administered twice per week for two months showed a potent COL I-up-regulating activity, leading to the increase of skin thickness (P < 0.05) without adverse reactions such as skin fibrosis. In human dermal fibroblasts, MβCD treatment induced up-regulated COL I and down-regulated Cav-1, supporting the results of mouse experiments. Collectively, MβCD has a COL I-enhancing activity in chronologically-aged skin, where Cav-1 acts as a brake in COL I expression, suggesting its potential role for an anti-aging agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.